Clinical trials: Head and Neck Squamous Cell Carcinomas
Esophageal Squamous Cell Carcinoma, Immunotherapy
Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma
This study aims to evaluate the efficacy of Camrelizumab plus concurrent chemotherapy as neoadjuvant approach for patients with opearble esophageal squamous cell carcinoma.
- Trial name
- NCT04225364
- Testing
- camrelizumab, Paclitaxel for injection (albumin-bound), Cisplatin
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Advanced Solid Tumors, Gastric Cancer
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
The purpose of this study is to assess the safety and effects of PF-07265028 as monotherapy and in combination with sasanlimab. The study aims to identify the maximum tolerated dose (MTD) of PF-07265028 as monotherapy; evaluate…
- Conditions
- Advanced Solid Tumors, Gastric Cancer, Gastroesophageal Junction Cancer, Urothelial Cancer
- Trial name
- NCT05233436
- Testing
- PF-07265028, Sasanlimab
- Where
- 8 sites in United States, Japan
- Volunteers
- 21 people
- Sponsor
- Pfizer
Head and Neck Cancer
Biomarkers in Patients With Metastatic or Recurrent Head and Neck Cancer Treated With Cisplatin and Cetuximab on ECOG-E5397
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment.
- Trial name
- NCT01466244
- Testing
- cetuximab, cisplatin, gene expression analysis
- Volunteers
- 42 people
- Sponsor
- Eastern Cooperative Oncology Group
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma
- Trial name
- NCT00030498
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Squamous Cell Carcinoma
Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid
This study evaluates the addition of valproic acid as a chemopreventive drug in head and neck squamous cell carcinoma (HNSCC) patients that do not have signs of recurrence or residual disease.
- Trial name
- GAMA (NCT02608736)
- Testing
- Valproic Acid
- Where
- Brazil
- Volunteers
- 42 people
- Sponsor
- Barretos Cancer Hospital
Head and Neck Neoplasms
TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma
The purpose of this trial is to evaluate the safety and efficacy of TransCon TLR7/8 Agonist, TransCon IL-2 β/γ, and pembrolizumab given prior to curative intent surgery in treatment of participants with newly diagnosed Stage…
- Trial name
- BelieveIT-201 (NCT05980598)
- Testing
- TransCon TLR7/8 Agonist, Pembrolizumab, TransCon IL-2 β/γ
- Where
- 65 sites in United States, Georgia and 6 more
- Volunteers
- 27 people
- Sponsor
- Ascendis Pharma A/S
Esophageal Neoplasms
Study of Simultaneous Modulated Accelerated Radiation Therapy Concurrent With Chemotherapy to Treat Esophageal Cancer
The purpose of this study is to evaluate the acute and 2-year late toxicities, the 2-year local control and overall survival rates in patients with esophageal squamous cell carcinoma receiving simultaneous modulated accelerated…
- Trial name
- NCT01670409
- Testing
- SMART, PF
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Chuangzhen Chen
Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL [LN-144/LN-145 (lifileucel)] in combination with immune checkpoint inhibitors or TIL…
- Conditions
- Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer
- Trial name
- NCT03645928
- Testing
- Lifileucel, LN-145, Pembrolizumab
- Where
- 34 sites in United States, Canada and 5 more
- Volunteers
- 225 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Lung Cancer Metastatic, Renal Cell Carcinoma
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
Immunotherapy (IO), such as treatment with anti-PD-1, PD-L1, or CTLA-4 inhibitors, is a rapidly expanding treatment for multiple metastatic cancers with improved survival for certain cancers.
- Conditions
- Lung Cancer Metastatic, Renal Cell Carcinoma, Head and Neck Cancer, Triple Negative Breast Cancer
- Trial name
- MOIO (NCT05078047)
- Testing
- Reduced dose intensity of IO
- Where
- 33 sites in France
- Volunteers
- 646 people
- Sponsor
- UNICANCER
Solid Tumor, Small Cell Lung Cancer (SCLC)
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.
- Conditions
- Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin
- Trial name
- NCT07517198
- Testing
- EXS74539
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Squamous Cell Carcinoma of the Head and Neck
A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck
A multicentre, open-label, non-randomized, phase Ib neoadjuvant study of intravenous NG-641, as monotherapy or in combination with pembrolizumab, in patients with surgically resectable squamous cell carcinoma of the head and neck…
- Trial name
- MOAT (NCT04830592)
- Testing
- NG-641, Pembrolizumab
- Where
- 4 sites in United Kingdom
- Volunteers
- 36 people
- Sponsor
- Akamis Bio
Metastatic Cancer, Solid Tumor
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
The primary purpose of this study is to see if Sym024 is safe and tolerable as monotherapy and in combination with Sym021 in patients with solid tumor malignancies.
- Trial name
- NCT04672434
- Testing
- Sym021, Sym024
- Where
- 4 sites in United States, Canada
- Volunteers
- 48 people
- Sponsor
- Symphogen A/S
Upper Aerodigestive Tract Lesions, Neoplasms, Oropharyngeal
Concordance of Two Endoscopic Procedures for Diagnosis of Carcinoma of the Upper Aerodigestive Tract
This study will compare TNFE-NBI and biopsy, with DRE and biopsy for the diagnostic evaluation and staging of patients with suspicious UADT lesions.
- Conditions
- Upper Aerodigestive Tract Lesions, Neoplasms, Oropharyngeal, Oropharyngeal Cancer, Neoplasms, Hypopharyngeal
- Trial name
- TNFE-NBI (NCT01175499)
- Testing
- Direct Rigid Endoscopy, Transnasal Flexible Endoscopy with Narrowband Imaging
- Sponsor
- University of California, San Francisco
Radiotherapy, Neoadjuvant Therapy
Postoperative Radiotherapy for Oral Squamous Cell Carcinoma After Neoadjuvant Therapy and Surgery
The treatment guideline for locally advanced resectable oral squamous cell carcinoma (LAROSCC) is surgery + postoperative radiotherapy/chemoradiotherapy.
- Conditions
- Radiotherapy, Neoadjuvant Therapy, Oral Squamous Cell Carcinoma, Surgery
- Trial name
- NCT05455632
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Esophageal Cancer
MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer
To further validate the performance of the high-sensitivity MRD assay in patients with squamous esophageal cancer who have completed radical radiotherapy; to validate whether MRD-negative patients can maintain a good prognosis…
- Trial name
- NCT06498752
- Testing
- PD-1 monoclonal antibody consolidation therapy
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Oropharyngeal Cancer, Human Papillomavirus
Human Papillomavirus (HPV) Oral Transmission Study in Partners Over Time
This research is being done to understand more about a sexually transmitted virus called Human papillomavirus (HPV) in people with oropharyngeal cancer and their partners.
- Trial name
- HOTSPOT (NCT01342978)
- Where
- 4 sites in United States
- Volunteers
- 242 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Head and Neck Cancer, Squamous Cell Cancer
Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer
Primary Objective: To determine the efficacy of the combination of imatinib mesylate and docetaxel in recurrent or metastatic head and neck squamous cell cancer by serial measurements of tumor response (extent, frequency…
- Trial name
- NCT00485485
- Testing
- Imatinib Mesylate, Docetaxel
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Esophageal Cancer
Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC
SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody. This is an openlabel，single center ，non-randomized ，Single Arm Exploratory Study . This clinical study is an investigator-initiated clinical trial（IIT).
- Trial name
- NCT03671265
- Testing
- SHR-1210, IMRT or VMAT, Apatinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Squamous Cell Carcinoma (ESCC)
BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study)
This is an open-label, single arm, multi-center study, assessing efficacy and safety of BI-754091 in combination with afatinib as treatment in patients with advanced or metastatic ESCC refractory to at least 1 line of systemic…
- Trial name
- BEAR (NCT04839471)
- Testing
- BI-754091 plus afatinib
- Where
- 4 sites in Taiwan
- Volunteers
- 49 people
- Sponsor
- National Health Research Institutes, Taiwan
Head and Neck Cancer
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00113399
- Testing
- filgrastim, cisplatin, docetaxel
- Where
- 125 sites in United States
- Volunteers
- 15 people
- Sponsor
- Radiation Therapy Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.